Cargando…
Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy
Mucopolysaccharidosis type II (MPSII) is a pediatric lysosomal storage disease caused by deficiencies in the IDS (iduronate-2-sulfatase) gene resulting in accumulation of glycosaminoglycans, multisystem disease, and profound neurodegeneration in severe forms. Although enzyme replacement therapy is a...
Autores principales: | Ellison, Stuart, Liao, Aiyin, Gleitz, Hélène F.E., Parker, Helen, Booth, Laura, Robinson, John, Wood, Shaun, Taylor, Jessica, Holley, Rebecca, Bigger, Brian W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618237/ https://www.ncbi.nlm.nih.gov/pubmed/37920237 http://dx.doi.org/10.1016/j.omtm.2023.101127 |
Ejemplares similares
-
Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II
por: Gleitz, Hélène F. E., et al.
Publicado: (2017) -
Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms
por: Gleitz, Hélène FE, et al.
Publicado: (2018) -
Glial degeneration with oxidative damage drives neuronal demise in MPSII disease
por: Zalfa, Cristina, et al.
Publicado: (2016) -
Haematopoietic stem cell gene therapy with IL‐1Ra rescues cognitive loss in mucopolysaccharidosis IIIA
por: Parker, Helen, et al.
Publicado: (2020) -
Pre-clinical Safety and Efficacy of Lentiviral Vector-Mediated Ex Vivo Stem Cell Gene Therapy for the Treatment of Mucopolysaccharidosis IIIA
por: Ellison, Stuart M., et al.
Publicado: (2019)